Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps the Government plans to take to ensure that the regulation of clinical trials is not weakened as the UK leaves the European Medicines Agency system.

The Medicines and Medical Devices Act 2021 provides targeted delegated powers which enable the regulatory regime for clinical trials to be updated. Using these powers we can design and strengthen a regulatory environment for clinical trials that will support the development of innovative medicines and e ensure that the regulation of trials is not weakened following the exit from the European Union.